Jefferies commented on Celgene (NASDAQ: CELG) after speaking to management about the European filing for Revlimid. The firm said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE